AmpliPhi Biosciences (Formerly known as Targeted Genetics)

281 articles with AmpliPhi Biosciences (Formerly known as Targeted Genetics)

• AmpliPhi Biosciences Successfully Optimizes Manufacturing Process and Scale Up for AB-SA01 Clinical Development

  12/18/2018

  AmpliPhi’s wholly owned GMP facility now capable of producing material for over 100,000 doses from each drug substance batch of AB-SA01, sufficient to support clinical trial requirements

• AmpliPhi Biosciences Reports Third Quarter 2018 Financial Results and Business Highlights

  11/8/2018

  The company intends to initiate one or more clinical trials in 2019 following positive FDA feedback

• 

  BioSpace Movers and Shakers - Oct. 22

  10/22/2018

  Execs at Novo Nordisk, AbbVie, and more made moves this week. Here's a roundup of those changes.

• AmpliPhi Biosciences Announces Closing of Public Offering

  10/16/2018

  AmpliPhi Biosciences Corporation today announced the closing of its previously announced underwritten public offering.

• AmpliPhi Biosciences Announces Pricing of $6.6 Million Underwritten Public Offering

  10/12/2018

  AmpliPhi Biosciences Corporation today announced the pricing of an underwritten public offering of 16,537,500 shares of its common stock

• AmpliPhi Biosciences Announces Presentation of Positive Clinical Data From its Expanded Access Program for Serious S. aureus Infections at IDWeek 2018 Conference

  10/8/2018

  13 patients with serious and life-threatening S. aureus infections were treated with AB-SA01 at the Westmead Hospital in Sydney under AmpliPhi’s expanded access program

• AmpliPhi Biosciences to Present Clinical Case Series Data at IDWeek 2018

  9/24/2018

  Professor Jonathan Iredell to present data from AmpliPhi Biosciences’ ongoing expanded access program for bacteriophage product candidates AB-SA01 (targeting S. aureus) and AB-PA01 (targeting P. aeruginosa)

• AmpliPhi Biosciences Announces Updated Positive Clinical Results for its Expanded Access Program

  9/17/2018

  AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced updated topline clinical results for its ongoing single-patient expanded access program

• AmpliPhi Biosciences Reports Second Quarter 2018 Financial Results and Business Highlights

  8/9/2018

  19 patients at 7 hospitals, with serious or life-threatening infections not responding to antibiotics, have been treated with AB-SA01 or AB-PA01 under single-patient expanded access program

• AmpliPhi Biosciences Announces Presentation of Bacteriophage Therapy Case Studies at American Society of Microbiology Annual Meeting

  6/7/2018

  AmpliPhi Biosciences Corporation announced a late-breaker poster presentation describing four case studies of patients suffering from severe Staphylococcus aureus (S. aureus) infections, who received treatment with AB-SA01, AmpliPhi’s investigational bacteriophage drug candidate.

• AmpliPhi Biosciences Announces Presentation of AB-PA01 Bacteriophage Therapy Case Study at 41st European Cystic Fibrosis Conference

  6/7/2018

  AmpliPhi Biosciences Corporation today announced a poster presentation of a successful case study of a patient with cystic fibrosis who received treatment with AB-PA01, AmpliPhi’s investigational bacteriophage drug candidate.

• AmpliPhi Biosciences Will Utilize NIAID Preclinical Services to Advance Development of Its Targeted Therapeutic Candidate for the Treatment of Resistant Staphylococcus Aureus

  5/3/2018

  AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it will utilize the Therapeutic Development Services funded by the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), to conduct further preclinical studies of AB-SA01

• AmpliPhi Biosciences Announces Closing of Registered Direct Offering of Common Stock

  3/22/2018

  AmpliPhi Biosciences Corporation (NYSE American: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced the closing of its previously announced registered direct offering of 2,743,640 shares of its common stock at a price of $1.10 per share.

• AmpliPhi Biosciences Announces Registered Direct Offering of Common Stock

  3/20/2018

  The offering is expected to close on or about March 22, 2018, subject to customary closing conditions.

• AmpliPhi to Collaborate with Western Sydney Local Health District and Westmead Institute for Medical Research on Expanded Access for Investigational Bacteriophage Therapeutics AB-SA01 and AB-PA01

  3/19/2018

  AmpliPhi Biosciences Corporation announced a collaboration with the Western Sydney Local Health District and the Westmead Institute for Medical Research, based in Sydney, Australia.

• AmpliPhi Biosciences Reports Fourth Quarter and Full Year 2017 Financial Results and Business Highlights

  3/14/2018

  AmpliPhi Biosciences Corporation announced financial results for the fourth quarter and full year ended December 31, 2017.

• AmpliPhi to Collaborate with the U.S. Department of Veterans Affairs on Expanded Access for Investigational Bacteriophage Therapeutics AB-SA01 and AB-PA01

  3/13/2018

  The agreement covers individual patient expanded access for AmpliPhi’s investigational bacteriophage therapeutics AB-SA01, targeting Staphylococcus aureus, and AB-PA01, targeting Pseudomonas aeruginosa.

• AmpliPhi Biosciences Announces Presentation of Preclinical Data Demonstrating that AB-PA01 Reduces Biofilm in Pseudomonas aeruginosa In Vivo Model

  3/9/2018

  The data was presented at the Australian Society of Otolaryngology Head and Neck Surgery 68th Annual Scientific Meeting, being held March 9-11, 2018 in Perth, Western Australia.

• AmpliPhi Biosciences Announces Proposed Public Offering of Common Stock

  1/10/2018

  AmpliPhi Biosciences today announced that it intends to offer shares of its common stock in a public offering.

• AmpliPhi Biosciences Announces Pricing of $4.0 Million Public Offering of Common Stock

  1/10/2018

  The offering is expected to close on or about January 12, 2018, subject to customary closing conditions.